Top

European Radiology

Published in:

01-06-2014 | Oncology

CT halo sign as an imaging marker for response to adoptive cell therapy in metastatic melanoma with pulmonary metastases

Authors: Shai Shrot, Jacob Schachter, Ronnie Shapira-Frommer, Michal J. Besser, Sara Apter

Published in: European Radiology | Issue 6/2014

Abstract

Objectives

The halo sign refers to a zone of ground-glass attenuation surrounding a pulmonary nodule. Pulmonary metastatic nodules exhibiting a halo sign are seen mainly in hypervascular tumours. We describe the appearance of a halo sign following treatment of adoptive transfer of autologous tumour-infiltrating lymphocytes (TIL) to melanoma patients with lung metastases.

Methods

The study included 29 melanoma patients with pulmonary metastases who received TIL therapy. Pre- and post-treatment chest CTs were retrospectively reviewed for the presence of a halo sign and its correlation with therapeutic response.

Results

A pulmonary halo sign was not seen in any pre-treatment CT. It was observed in four of 12 patients who responded to the therapy but not in those who failed to respond. Significant differences were found between response ratio in patients in whom post-TIL halo sign appeared compared with those without the halo sign (p = 0.02).

Conclusions

The appearance of a CT halo sign in melanoma with lung metastases following TIL therapy may indicate antitumoral effect and a good response to therapy. Our findings emphasize the importance of applying new assessment criteria for immunological anticancer therapies.

Key Points

• Tumour-infiltrating lymphocytes (TIL) in melanoma patients is a promising novel immunotherapy

• Post-therapy pulmonary halo sign appeared in one-third of TIL responders

• Pulmonary halo sign may serve as an imaging marker for antitumoral activity

Dreno B, Nguyen JM, Khammari A, Pandolfino MC, Tessier MH, Bercegeay S, Cassidanius A, Lemarre P, Billaudel S, Labarriere N, Jotereau F (2002) Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 51:539–546PubMedCrossRef

Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21:233–240PubMedCentralPubMedCrossRef

Lee YR, Choi YW, Lee KJ, Jeon SC, Park CK, Heo JN (2005) CT halo sign: the spectrum of pulmonary diseases. Br J Radiol 78:862–865PubMedCrossRef

Primack SL, Hartman TE, Lee KS, Muller NL (1994) Pulmonary nodules and the CT halo sign. Radiology 190:513–515PubMed

Kaneria SS, Tarkin J, Williams G, Bain G, Quigley M (2012) Case report: the CT halo sign: a rare manifestation of squamous cell carcinoma of the lung. Clin Radiol 67:613–615PubMedCrossRef

Okita R, Yamashita M, Nakata M, Teramoto N, Bessho A, Mogami H (2005) Multiple ground-glass opacity in metastasis of malignant melanoma diagnosed by lung biopsy. Ann Thorac Surg 79:e1–e2PubMedCrossRef

Shapira-Frommer R, Schachter J (2012) Adoptive immunotherapy of advanced melanoma. Curr Treat Options in Oncol 13:340–353CrossRef

Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J (2010) Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 16:2646–2655PubMedCrossRef

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef

10.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef

11.

Marten K, Rummeny EJ, Engelke C (2004) The CT halo: a new sign in active pulmonary sarcoidosis. Br J Radiol 77:1042–1045PubMedCrossRef

12.

Cole DJ, Taubenberger JK, Pockaj BA, Yannelli JR, Carter C, Carrasquillo J, Leitman S, Steinberg SM, Rosenberg SA, Yang YC (1994) Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes. Cancer Immunol Immunother 38:299–303PubMedCrossRef

13.

Fisher B, Packard BS, Read EJ, Carrasquillo JA, Carter CS, Topalian SL, Yang JC, Yolles P, Larson SM, Rosenberg SA (1989) Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 7:250–261PubMed

14.

Griffith KD, Read EJ, Carrasquillo JA, Carter CS, Yang JC, Fisher B, Aebersold P, Packard BS, Yu MY, Rosenberg SA (1989) In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 81:1709–1717PubMedCrossRef

15.

Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF, Carasquillo JA, Steinberg SM, Rosenberg SA, Yang JC (1994) Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 73:1731–1737PubMedCrossRef

16.

Zhou J, Dudley ME, Rosenberg SA, Robbins PF (2005) Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 28:53–62PubMedCentralPubMedCrossRef

17.

Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J (2010) Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102:1388–1397PubMedCentralPubMedCrossRef

Title: CT halo sign as an imaging marker for response to adoptive cell therapy in metastatic melanoma with pulmonary metastases
Authors: Shai Shrot
Jacob Schachter
Ronnie Shapira-Frommer
Michal J. Besser
Sara Apter
Publication date: 01-06-2014
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 6/2014
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-014-3129-6

At a glance: The STEP trials

Springer Medicine

CT halo sign as an imaging marker for response to adoptive cell therapy in metastatic melanoma with pulmonary metastases

Abstract

Objectives

Methods

Results

Conclusions

Key Points

At a glance: The STEP trials

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Please log in to get access to this content

Other articles of this Issue 6/2014

Intraosseous rotation of the scaphoid: assessment by using a 3D CT model—an anatomic study

Radial volumetric imaging breath-hold examination (VIBE) with k-space weighted image contrast (KWIC) for dynamic gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI of the liver: advantages over Cartesian VIBE in the arterial phase

Quantitative sodium MR imaging of native versus transplanted kidneys using a dual-tuned proton/sodium (1H/23Na) coil: initial experience

Diagnostic accuracy of segmental enhancement inversion for diagnosis of renal oncocytoma at biphasic contrast enhanced CT: systematic review

Application of the diffusion kurtosis model for the study of breast lesions

Gastrointestinal tract perforation: evaluation of MDCT according to perforation site and elapsed time